6 Results

People

  1. Chapman
    Chapman
  2. Carvajal
    Carvajal
  3. Postow
    Postow
  4. Romano
    Romano
  5. Schwartz
    Schwartz

Groups

  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (6)
  2. Department of Medicine (6)
  3. Melanoma and Immunotherapeutics Service (6)
  4. Solid Tumor Oncology Division (6)
  5. Melanoma Disease Management Team (1)
  1. "Department of Medicine"
  2. "Paul Chapman"
  3. "Lancet Oncology"
  4. "Elsevier Science, Inc."
Formats
  1. Journal Article (6)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (6)
  2. Department of Medicine (6)
  3. Melanoma and Immunotherapeutics Service (6)
  4. Solid Tumor Oncology Division (6)
  5. Melanoma Disease Management Team (1)
People
  1. Paul Chapman (6)
  2. Emanuela Romano (1)
  3. Gary Schwartz (1)
  4. Michael Postow (1)
  5. Richard Carvajal (1)
Years
  1. 2018 (2)
  2. 2017 (1)
  3. 2014 (1)
  4. 2012 (1)
  5. 2011 (1)
Publications
  1. Lancet Oncology (6)
Publishers
  1. Elsevier Science, Inc. (6)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Changing the standard of care for treating melanoma brain metastases
    Journal Article

    Chapman, P. B.
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: A retrospective, multicohort analysis
    Journal Article

    McQuade, J. L.; Daniel, C. R.; Hess, K. R.; Mak, C.; Wang, D. Y.; Rai, R. R.; Park, J. J.; Haydu, L. E.; Spencer, C.; Wongchenko, M.; more...
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • A step forward for patients with NRAS-mutant melanoma
    Journal Article

    Postow, M. A.; Chapman, P. B.
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study
    Journal Article

    McArthur, G. A.; Chapman, P. B.; Robert, C.; Larkin, J.; Haanen, J. B.; Dummer, R.; Ribas, A.; Hogg, D.; Hamid, O.; Ascierto, P. A.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial
    Journal Article

    Long, G. V.; Trefzer, U.; Davies, M. A.; Kefford, R. F.; Ascierto, P. A.; Chapman, P. B.; Puzanov, I.; Hauschild, A.; Robert, C.; Algazi, A.; more...
    Lancet Oncology (2012)

    Fulltext@MSK | Save
  • Treatment implications of the emerging molecular classification system for melanoma
    Journal Article

    Romano, E.; Schwartz, G. K.; Chapman, P. B.; Wolchock, J. D.; Carvajal, R. D.
    Lancet Oncology (2011)

    Fulltext@MSK | Save